Porcine Vaccine Global Market Report 2024

The porcine vaccine market size has grown strongly in recent years. It will grow from $1.74 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth observed in the historical period can be attributed to several factors, including disease outbreaks and corresponding control measures, a global increase in pork consumption, the intensification of pig farming practices, government initiatives focused on disease control in the pig farming sector, and awareness and education programs aimed at enhancing disease prevention and management.

The porcine vaccine market size is expected to see strong growth in the next few years. It will grow to $2.73 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth in the forecast period can be attributed to several factors, including the global expansion of pig farming, the increasing challenges posed by diseases, the implementation of stringent regulations and compliance measures, technological advancements in vaccine development, and efforts in global trade to mitigate disease risks. Key trends expected during this period include the customization of vaccines to address regional challenges, the integration of biotechnology in vaccine development, growing concerns about zoonotic diseases, the application of genomic approaches in vaccine design, and a rise in investments in research and development within the industry.

The anticipated growth in the porcine vaccine market is expected to be driven by the increasing incidence of swine diseases. Swine influenza (swine flu), caused by the type A influenza virus, is a respiratory illness that commonly affects pigs, leading to influenza outbreaks in swine populations. Porcine vaccines play a crucial role in preventing and controlling such diseases. These vaccines stimulate the swine's immune system, allowing it to effectively respond to the pathogenic agent and develop an immunogenic reaction. By preparing the swine's immune system, porcine vaccines enable the prevention of diseases and trigger an anamnestic reaction upon encountering the same pathogen. For example, the Swine Health Information Centre reported 1,844 outbreaks of African Swine Fever (ASF) in domestic pigs across European countries in the year 2021. This highlights the significance of porcine vaccines in addressing the rising infection of swine diseases and driving the growth of the porcine vaccine market.

The increasing consumption of pork is expected to contribute to the growth of the porcine vaccine market. As the global population grows, there is a rising demand for protein, leading to an increase in pork consumption. To meet this demand efficiently, pig farming has become more intensive, making vaccinations essential for maintaining the health and productivity of pig herds. For instance, in March 2022, Pig333 reported that pork consumption in China was approximately 61, 52, and 37 kg per inhabitant. The projections indicate a 4.1% growth in consumption in China by 2022, reaching almost 52 kg per inhabitant. This upward trend in pork consumption underscores the importance of porcine vaccines in supporting the health and sustainability of pig farming, thereby driving the growth of the porcine vaccine market.

Major companies engaged in the porcine vaccine market are actively focusing on the development of innovative products, exemplified by the introduction of a new swine vaccine designed to safeguard pigs from various syndromes. Swine vaccines play a vital role in swine health management by protecting pigs from diverse diseases. An illustrative example is the launch of FLEX ParvoPRRS by Boehringer Ingelheim, a Germany-based vaccine manufacturing company, in September 2021. This groundbreaking vaccine combines the efficacy and safety of industry-leading Reprocyc ParvoFLEX for Porcine Parvovirus (PPV) and Ingelvac PRRSFLEX MLV for Porcine Reproductive and Respiratory Syndrome (PRRS). Addressing two significant threats to swine health, this vaccine aims to enhance reproductive health and productivity, ensuring better breeding herds and larger litters. Importantly, it is deemed safe for all stages of breastfeeding and gestation, supporting mass vaccination strategies in breeding herds.

The noteworthy development involves major companies in the porcine vaccine market introducing innovative products such as the 3-in-one swine vaccine, offering enhanced protection against various diseases. Merck Animal Health, a US-based pharmaceutical company, launched Circumvent CML in June 2023. This three-in-one vaccine controls Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. The product provides convenience and assurance to producers and caregivers, simplifying the vaccination process and reducing the number of injections for younger pigs. Built on a foundation of proven adjuvant systems and antigens, Circumvent CML signifies a novel approach in swine vaccination.

In October 2021, Vaxxinova International BV, a Netherlands-based company specializing in animal health solutions, including vaccines, diagnostics, and feed additives, acquired Newport Labs from Boehringer Ingelheim for an undisclosed amount. This acquisition reflects Vaxxinova International BV's commitment to expanding its presence in cattle and swine disease. Newport Labs, a US-based laboratory company, specializes in producing custom-made vaccines for swine and cattle, contributing to Vaxxinova's goal of enhancing products and services for livestock producers and veterinarians.

Major companies operating in the porcine vaccine market report are Bayer AG, Sanofi Pasteur Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Zoetis Inc., Arko Laboratories Limited, Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., Ringpu Bio-Pharmacy Co. Ltd., IDT Biologika GmbH, Bimeda Holdings PLC, Jinyu Bio-Technology Co. Ltd., Biogénesis Bagó, ProBioGen AG, Pharmaq AS, Veterquimica S.A., Kyoto Biken Laboratories Inc., Dopharma Research B.V., Agrovet Market Animal Health Ltd., Innovad SA, PBS Animal Health, Merial Animal Health, Biozoo S.A., Aptimmune Biologics Inc., Syntex SA de CV, Zoovet S.A., Shenzhen Weierkang Xiang Animal Pharm Co. Ltd., Wuhan Keqian Biology Co. Ltd., Anicon Labor GmbH.

North America is the largest region in the porcine vaccine market in 2023. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the porcine vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

In the realm of porcine vaccines, major technologies include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. Inactivated vaccines, for instance, are made from killed or inactivated viruses or bacteria and stimulate an immune response to protect pigs against natural infections. These vaccines are employed to address various diseases such as diarrhea, swine influenza, arthritis, bordatella rhinitis, porcine reproductive and respiratory virus (PRRSV), porcine circovirus-associated disease (PCVAD), and others, commonly utilized in hospitals and pig production farms.

The porcine vaccines market research report is one of a series of new reports that provides porcine vaccines market statistics, including porcine vaccines industry global market size, regional shares, competitors with a porcine vaccines market share, detailed porcine vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the porcine vaccines industry. This porcine vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The porcine vaccines market consists of sales of antibacterial vaccines and antiviral vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.